Experimental approach to improve endothelial barrier function in myocardium

International Journal of Angiology

Volumn 8, Issue 2, 1999, Pages 119-123

  Wozniak, Gernold ^a   Noll, Thomas ^a   Dapper, Friedhelm ^a   Piper, Hans Michael ^a   Hehrlein, Friedrich Wilhelm ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13;

ANIMAL CELL; AORTA; ARTICLE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART MUSCLE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASCULAR ENDOTHELIUM; WATER CONTENT;

EID: 0032944221     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01616829     Document Type: Article

References (27)

1. 1. Albelda SM, Sampson PM, Haselton FR, McNiff JM, Mueller SN, Williams SK, Fishman AP, Levine EM (1988) Permeability characteristics of cultured endothelial cell monolayers. J Appl Physiol 64: 308-322.
2. 2. Garcia JGN, Verin AD, Schaphorst KL (1996) Regulation of thrombin-mediated endothelial cell contraction and permeability. Sem Thromb Hemost 22:309-315.
3. 3. Noll T, Muhs A, Besselmann M, Watanabe H, Piper HM (1995) Initiation of hyperpermeability in energy-depleted coronary endothelial monolayers. Am J Physiol 268:H1462-1470.
4. 4. Hakimi M, Walters HL, Pinsky WW, Gallagher MJ, Lyons JM (1994) Delayed sternal closure after neonatal cardiac operations. J Thorac Cardiovasc Surg 107:925-933.
5. 5. Odim JNK, Tschervenkov CI, Dobell ARC (1989) Delayed sternal closure: A lifesaving maneuver after early operation for complex congenital heart disease in the neonate. J Thorac Cardiovasc Surg 98:413-416.
6. 6. Wozniak G, Noll T, Bauer J, Schindler E, Görlach G, Schranz D, Dapper F, Piper HM, Hehrlein FW (1998) Experimental investigation of therapeutic approach for decrease of endothelial barrier function in myocardium. Thorac Cardiovasc Surg (in press).
7. 7. Aoki N, Harpel PC (1984) Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 10:24-41.
8. 8. Shafer JA, Higgins DL (1988) Human fibrinogen. Crit Rev Clin Lab Sci 26:1-41.
9. 9. Muszbek L, Adany R, Mikkola H (1996) Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function. Crit Rev Clin Lab Sci 33:357-421.
10. 10. Knox P, Crooks S, Rimmer CS (1986) Role of fibronectin in the migration of fibroblasts into plasma clots. J Cell Biol 102:2318-2323.
11. 11. Ueki S, Takagi J, Saito Y (1996) Dual functions of transglutaminase in novel cell adhesion. J Cell Sci 109:2727-2735.
12. 12. Lorand L, Losowsky MS, Miloszewski KJ (1980) Human factor XIII: Fibrin-stabilizing factor. Prog Hemost Thromb 5:245-290.
13. 13. Mosher DF, Schad PE (1979) Cross-linking of fibronectin to collagen by blood coagulation Factor XIIIa. J Clin Invest 64:781-787.
14. 14. Suzuki R, Toda H, Takamura Y (1989) Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut 59:162-164.
15. 15. Wozniak G, Dapper F, Alemany J (1996) Factor XIII in ulcerative leg disease: Background and preliminary clinical results. Sem Thromb Hemost 22:445-450.
16. 16. Keski Oja J, Mosher DF, Vaheri A (1976) Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII. Cell 9:29-35.
17. 17. Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS (1988) Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 157:115-120.
18. 18. Pilger E, Bertuch H, Ulreich A, Rainer F (1987) Capillary permeability in connective tissue disease: Influence of Fibrogammin P-therapy. Thromb Haemost 58:279.
19. 19. Spahr R, Piper HM (1990) Microcarrier cultures of endothelial cells. In: Cell Culture Technique in Heart and Vessel Research, Piper HM (ed). Springer-Verlag: Berlin, pp 220-229.
20. 20. Sibelius U, Hattar K, Schenkel A, Noll T, Csernok E, Gross WL, Mayet WJ, Piper HM, Seeger W, Grimminger F (1998) Wegeners granulomatosis: Anti-proteinase 3 antibodies are potent inductors of human endothelial cell signalling and leakage response. J Exp Med 187:497-503.
21. 21. Wozniak G, Noll T, Dapper F, Piper HM, Hehrlein FW (1998) Fibrin stabilizing factor as a topical means for leg ulcer healing: Biochemical and experimental properties and clinical results. Int J Angiol 7:109-114.
22. 22. Buderus S, Siegmund B, Spahr R, Krutzfeldt A, Piper HM (1989) Resistance of endothelial cells to anoxia-reoxygenation in isolated guinea pig hearts. Am J Physiol 257:H488-H493.
23. 23. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED (1997) Endothelial cell injury in cardiovascular surgery: The systemic inflammatory response. Ann Thorac Surg 63:277-284.
24. 24. Garcia JGN, Painter RG, Fenton II JW (1990) Thrombin-induced prostacyclin biosynthesis in human endothelium: Role of guanine nucleotide regulatory proteins in stimulus/coupling responses. J Cell Physiol 142:186-193.
25. 25. Guretzki HJ, Gerbitz KD, Olgemölled B, Schleicher E (1994) Atherogenic levels of low density lipoprotein alter the permeability and composition of the endothelial barrier. Atherosclerosis 107:15-24.
26. 26. Inserte J, Garcia-Dorade D, Ruiz-Meana M, Solares J, Soler JS (1997) The role of Na+-H+exchange occuring during hypoxia in the genesis of reoxygenation-induced myocardial edema. J Mol Cell Cardiol 29: 1167-1175.
27. 27. Utani A, Ohta M, Shinya A, Ohno S, Takakuwa H, Yamamoto T, Suzaki T, Danno K (1991) Successful treatment of adult Henoch-Schonlein purpura with factor XIII concentrate. J Am Acad Dermatol 24:438-442.